A Comparison of the Efficacy and Safety of Modified Baerveldt Drainage Implants versus Ahmed Glaucoma Valves After 1 Year of Follow-Up.

Authors

Kristin L Davis, Quinton H Christensen, Joel A VandeLune, Danielle R Pellack, Patrick J Donegan, Matthew D Meyer, Ronak S Singh, Hend M Al-Kaylani, Erin A Boese, Andrew E Pouw

Published in

Clinical ophthalmology (Auckland, N.Z.). Volume 20. Pages 588163. Epub Jul 08, 2026.

Abstract

A modification to the Baerveldt Glaucoma Implant allows for earlier postoperative intraocular pressure (IOP) reduction. The goal of this study was to evaluate the efficacy and safety of this modification (vsBGI) compared to the Ahmed Glaucoma Valve (AGV) out to 1 year of follow-up.
This retrospective cohort study included 124 eyes from patients aged ≥18 years with glaucoma who underwent implantation of vsBGIs or AGVs. Longitudinal outcomes were analyzed using adjusted linear mixed-effects models to account for baseline differences. Kaplan-Meier survival curves were used to compare surgical success. The primary outcomes were IOP and number of medications.
A total of 124 eyes were included (62 AGV and 62 vsBGI). Preoperative IOP was found to be significantly higher in the AGV group prior to surgery. At 1 year, median IOP reduction was similar between groups. Kaplan-Meier analysis showed no significant between-group difference under the liberal (≤21 mmHg), conservative (≤14 mmHg), or individualized target-IOP criteria, whereas the vsBGI group showed higher survival probability at the intermediate threshold criterion (≤17 mmHg). The vsBGI group required significantly fewer medications on Day 1. No statistically significant differences in postoperative complication frequency or type were observed between groups.
The vsBGI showed broadly comparable 1-year efficacy and safety to the AGV, with similar IOP reduction and surgical survival, fewer early postoperative medications, and comparable visual acuity and adverse event rates.

PMID:
42438751
Bibliographic data and abstract were imported from PubMed on 13 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.